USABiotech & Genomic Medicine▲
MaxCyte signs multi-platform technology license partnership with Genentech
MaxCyte has entered into a multi-platform technology license partnership with Genentech, a member of the Roche Group, to advance next-generation cell therapy programs. The agreement gives Genentech access to MaxCyte's ExPERT GTx platform and additional platform technologies across select research, clinical development, and manufacturing workflows, supporting multiple programs for ex vivo cell engineering. MaxCyte stated its platforms are designed to streamline cell therapy advancement from early discovery through cGMP manufacturing. The partnership combines complementary capabilities in cell engineering and gene editing to provide broader support across the cell therapy lifecycle. MaxCyte stock closed Tuesday at $1.23, up 5.13%, and was up 0.80% in after-hours trading.